Several brokerages have updated their recommendations and price targets on shares of Candel Therapeutics (NASDAQ: CADL) in the last few weeks:
- 10/22/2026 – Candel Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $25.00 price target on the stock.
- 10/22/2026 – Candel Therapeutics is now covered by Jefferies Financial Group. They set a “buy” rating and a $25.00 price target on the stock.
- 10/15/2026 – Candel Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/14/2026 – Candel Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/2/2026 – Candel Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
- 9/21/2026 – Candel Therapeutics was upgraded by Bank of America from “neutral” to “buy”. They now have a $18.00 price target on the stock, up from $12.00.
Insider Transactions at Candel Therapeutics
In related news, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $12.00, for a total transaction of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares in the company, valued at $922,380. This trade represents a 8.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.30% of the stock is currently owned by insiders.
Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.
Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.
Read More
- Five stocks we like better than Candel Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Candel Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
